The drug development industry has welcomed the UK government’s position paper seeking a smooth and orderly withdrawal from the European Union (EU) in regard to the availability of goods, in a way that supports the move to the freest possible future economic relationship.
This paper, entitled Continuity in the availability of goods for the EU and the UK, was published on Monday and makes the UK government position somewhat clearer on what the future relationship with the EU will look like on these key issues for investors and businesses once Brexit has happened and during the transition period.
“The UK’s ambition is to work towards a comprehensive future agreement with the EU, which includes securing the freest and most frictionless trade possible in goods and services, to the benefit of all,” the paper states. “The UK enters these discussions with this in mind, and is seeking to avoid any unnecessary disruption during the move to the future partnership."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze